Skip to main content
Malin Corporation Plc logo

Malin Corporation Plc — Investor Relations & Filings

Ticker · MLC ISIN · IE00BVGC3741 LEI · 635400JG4YSDU5U1YU17 IR Financial and insurance activities
Open in API
Filings indexed 180 across all filing types
Latest filing 2023-02-16 Report Publication Anno…
Country IE Ireland
Listing IR MLC

About Malin Corporation Plc

http://malinplc.com/

Malin Corporation Plc is an investment company that provides long-term capital and operational expertise to highly innovative life sciences companies. The company focuses on private businesses operating in the therapeutics, medical devices, and diagnostics sectors. Its investment strategy is concentrated on specific therapeutic areas, primarily oncology, immunology, and genetic diseases. Malin supports its portfolio companies across various stages of development, from initial science and discovery through to clinical and commercial phases, with the objective of fostering the development of transformative technologies and outcomes for patients.

Recent filings

Filing Released Lang Actions
2022 Full Year Results & Notice of AGM
Report Publication Announcement Classification · 99% confidence The document explicitly states it 'today publishes its full year results and annual report for the year ended 31 December 2022.' This strongly indicates the content is the Annual Report (10-K equivalent for non-US filers, but based on the definition provided, 10-K is the closest fit for a 'Full Year Results and Annual Report'). Furthermore, it mentions the 'Notice of Annual General Meeting ("AGM")' and provides details for the AGM, which often accompanies the Annual Report. Since the document contains the full year results and annual report content (financial estimates, investee highlights, cash position for the full year 2022), it should be classified as the report itself, not just an announcement of publication (RPA). The length (10101 chars) also supports it being the report content rather than a brief RPA.
2023-02-16 English
Holding(s) in Company
Director's Dealing Classification · 98% confidence The document is identified by the header 'RNS Number' and contains a notification regarding a change in shareholding interest by a director/insider ('Mr Sean O'Driscoll' holding 5.3% of the issued share capital). This directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content is about insider transactions, making DIRS the most precise classification over the general RNS category.
2023-01-23 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is clearly identified by the 'RNS Number : 7281M' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a transaction by a Person Discharging Managerial Responsibilities (PDMR) regarding the vesting of Restricted Share Units (RSUs) for a Company Director (WILLIAM DANIEL). This type of insider transaction disclosure falls under the category of Director's Dealing (DIRS). Although it is distributed via RNS, the specific subject matter is insider trading/dealing, making DIRS the most precise classification over the general RNS fallback.
2023-01-13 English
Holding(s) in Company
Director's Dealing Classification · 98% confidence The document is identified by the header 'RNS Number' and contains information about a change in shareholding by a director ('Mr Sean O'Driscoll'). Specifically, it details that he holds 1,450,000 ordinary shares, representing 4.265% of the issued share capital. This directly corresponds to the definition of 'Director's Dealing' (insider trades/personal share transactions by directors). Although it is distributed via RNS, the specific content points to DIRS over the general RNS category. The document length is short (1600 chars), but the content is substantive regarding insider trading, not just announcing a report.
2022-12-12 English
Business Updates
Earnings Release Classification · 99% confidence The document is identified by the RNS Number header and the footer explicitly stating, "This information is provided by RNS, the news service of the London Stock Exchange." The content details significant business updates, including the sale of an investment (Immunocore), current cash position, plans for a capital return via a tender offer, and an updated intrinsic equity value per share based on investee company valuations. This structure—a formal announcement of material, non-public information released via an official regulatory news service—is characteristic of a general regulatory announcement. Since it is not a full Annual Report (10-K), a specific Earnings Release (ER), or a detailed Interim Report (IR), and it is a direct announcement rather than a report publication announcement (RPA), the most appropriate classification is the general regulatory filing category. Q2 2022
2022-12-07 English
Block listing Interim Review
Share Issue/Capital Change Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content is a 'Schedule 6 - BLOCK LISTING SIX MONTHLY RETURN' detailing the balance of unallotted securities under an incentive plan over a six-month period (May 2022 to November 2022). This type of routine regulatory disclosure, which doesn't fit into specific financial reports (10-K, IR, ER) or corporate actions (DIV, SHA, POS), is best classified under the general regulatory announcement category, RNS, as it is a standard filing disseminated via the RNS system.
2022-11-04 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.